GUIDOSS

K133507 · Nibec Co., Ltd. · NPL · Nov 5, 2014 · Dental

Device Facts

• Record ID: K133507
• Device Name: GUIDOSS
• Applicant: Nibec Co., Ltd.
• Product Code: NPL · Dental
• Decision Date: Nov 5, 2014
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 872.3930
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

GuidOss® is recommended for: Simultaneous use of membrane (GuidOss®) and implants : 1. Augmentation around implants placed in immediate extract sockets; 2. 3. Augmentation around implants placed in delayed extraction sockets; 4. Localized ridge augmentation for later implantation; 5. Alveolar ridge reconstruction for prosthetic treatment 6. Filling of bone defects after root resection, cystectomy, removal of retained teeth. 7. Guided bone regeneration in dehiscence defects; and 8. Guided tissue regeneration procedures in periodontal defects.

Device Story

GuidOss is a resorbable, porcine-derived type I collagen membrane; manufactured via fibrillogenesis and crosslinking to enhance mechanical strength, thermal stability, and resistance to pepsin digestion. Used by dental clinicians in oral/periodontal surgery; acts as a physical barrier to facilitate guided bone and tissue regeneration. Placed over bone defects or around implants to prevent soft tissue ingrowth; allows bone regeneration. Resorbs over time; biocompatible. Benefits include improved defect healing and bone quality for subsequent dental implant placement.

Clinical Evidence

Evidence includes bench testing (biocompatibility per ISO 10993, genotoxicity, cytotoxicity, sensitization, pyrogenicity, implantation), animal studies comparing bone growth and resorption rates to predicates, and a clinical case series demonstrating defect healing and bone formation sufficient for dental implant placement.

Technological Characteristics

Resorbable membrane composed of purified porcine type I collagen. Manufactured via fibrillogenesis and crosslinking. Sterilized by gamma irradiation. Shelf-life of 36 months. Supplied in double blisters.

Indications for Use

Indicated for human oral and periodontal procedures requiring guided bone or tissue regeneration, including augmentation around dental implants, alveolar ridge reconstruction, and filling of bone defects following root resection, cystectomy, or tooth removal.

Regulatory Classification

Identification

Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.

Special Controls

*Classification.* (1) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)(2) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Bio-Gide® Resorbable Bilayer Membrane for Guided Tissue and Bone Regeneration (K050446)
• CollaDental Barrier, Collagen dental matrix, Dressing, Wound (K100695)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features the department's name in a circular arrangement around a symbol. The symbol consists of three stylized human profiles facing right, with flowing lines representing hair or clothing. The logo is black and white.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

November 5, 2014

Nibec Company Limited C/O Mr. Daniel Nam PATs Corporation General Manager 4568 W. 1st Street, Suite 104 Los Angeles, CA 90004

Re: K133507

Trade/Device Name: GuidOss® Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Grafting Material Regulatory Class: II Product Code: NPL Dated: September 2, 2014 Received: September 8, 2014

#### Dear Mr. Nam:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Page 2 - Mr. Nam

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Susan Runno DDS, mA

Erin I. Keith, M.S. Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health

{2}------------------------------------------------

#### Indications for Use Statement

#### INDICATION FOR USE

K133507 510(k) Number:

GuidOss® Device Name:

#### INDICATIONS FOR USE:

GuidOss® is recommended for:

- Simultaneous use of membrane (GuidOss®) and implants : 1.
- Augmentation around implants placed in immediate extract sockets; 2.
- 3. Augmentation around implants placed in delayed extraction sockets;
- 4. Localized ridge augmentation for later implantation;
- 5. Alveolar ridge reconstruction for prosthetic treatment
- 6. Filling of bone defects after root resection, cystectomy, removal of retained teeth.
- 7. Guided bone regeneration in dehiscence defects; and
- 8. Guided tissue regeneration procedures in periodontal defects.

Prescription Use

AND/OR

Over-The-Counter Use

(Part 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)

Concurrence of CDRH, Office of Device Evaluation (ODE)

{3}------------------------------------------------

# 510(k) Summary

## Sponsor/Applicant

NIBEC Co., Ltd. Iwol electricity-electronic Agro-industrial Complex, 1127, Sinwol-ri, Iwol-myeon, Jincheon-gun, Chungcheongbuk-do, Korea Phone: [phone] Fax: [phone] Contact: Dr. Park, Yoon-Jeong

Date Prepared : October 24, 2013

### Device Name and Identification

| Proprietary Name: | GuidOss® |
|----------------------|-----------------------------------|
| Common/Usual Name: | Resorbable Collagen Membrane |
| Classification Name: | Barrier, Animal Source, Intraoral |

#### Predicate devices

Bio-Gide® Resorbable Bilayer Membrane for Guided Tissue and Bone Regeneration (K050446)

Manufactured by: Geistlich Pharma AG Bahnhofstrasse 40 CH-6110 Wolhusen Switzerland

CollaDental Barrier, Collagen dental matrix, Dressing, Wound (K100695) Manufactured by: Collamatrix Inc. 1F, No. 50-1, Keyan Road, Jhunan Science Park Miaoli County, 350, Taiwan

#### Device Category/Class

| Device Class: | Class II |
|--------------------|--------------------|
| Regulation Number: | 21 C.F.R. 872.3930 |
| Product Code: | NPL |

#### Indication for use

GuidOss® is recommended for:

- Simultaneous use of membrane (GuidOss®) and implants : 1.
- Augmentation around implants placed in immediate extract sockets; 2.
- 3. Augmentation around implants placed in delayed extraction sockets;
- 4. Localized ridge augmentation for later implantation;
- Alveolar ridge reconstruction for prosthetic treatment 5.
- 6. Filling of bone defects after root resection, cystectomy, removal of retained teeth.

{4}------------------------------------------------

- 7. Guided bone regeneration in dehiscence defects; and
- 8. Guided tissue reqeneration procedures in periodontal defects.

## Device Description

GuidOss® is made from pure type I collagen membrane obtained by a standardized controlled manufacturing process. The type I collagen is obtained from veterinary certified porcine and is carefully purified to avoid immunological reactions. GuidOss® membrane is manufactured by fibrillogenesis and crosslinking. The collagen fibers are self-assembled by the process of fibrillogenesis. The crosslinked collagen fibers exhibited increased mechanical strength, thermal stability and increased resistance to pepsin digestion compared to non-crosslinked collagen.

## Basis for Substantial Equivalence

GuidOss® resorbable collagen membrane Consists of Material (porcine Collagen) that is very similar in material composition to the predicate devices, Bio-Gide® (porcine Type 1, 3 Collagen), CollaDental Barrier® (porcine Type 1 Collagen). Design, function and intended use are substantially equivalent to the corresponding characteristics of the predicate devices. Although minor differences exist in terms of manufacturing processing, medical device packaging, and handling characteristics GuidOss resorbable collagen membrane and the two predicate devices, these minor differences raise no new issues of safety and efficacy of GuidOss® resorbable collagen membrane.

The following is a table comparing GuidOss®, Bio-Gide® and CollaDental Barrier® a collagen membrane cleared for GTR and GBR.

| Property | GuidOss® | Bio-Gide® | CollaDental Barrier® |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| | | (K050446) | (K100695) |
| Similar<br>Intended Use | Used for guided tissue<br>regeneration procedures<br>in periodontal defects to<br>enhance regeneration of<br>the periodontal<br>apparatus. | Used for guided tissue<br>regeneration procedures<br>in periodontal defects to<br>enhance regeneration of<br>the periodontal<br>apparatus. | Used for guided tissue<br>regeneration procedures<br>in periodontal defects to<br>enhance regeneration of<br>the periodontal<br>apparatus. |
| Target population | Human oral, periodontal | Human oral, periodontal | Human oral, periodontal |
| Dosage form | Collagen membrane<br>contained in double<br>blisters | Collagen membrane<br>contained in double<br>blisters | Collagen membrane<br>contained in double<br>blisters |
| Material | Type I collagen | Type I and Type III<br>collagen | Type I collagen |
| Animal source | porcine | porcine | porcine |
| Physical<br>Morphology | Collagen fibers | Collagen fibers | Collagen fibers |
| Biocompatible | Biocompatible, as<br> | Biocompatible (as<br>demonstrated<br>in | Biocompatible (as<br>demonstrated<br>in |

## Table 1: Substantial Equivalence Comparison

{5}------------------------------------------------

| | demonstrated by : | published literature) | published literature) |
|----------------------------------|-----------------------------------------------|--------------------------------------------|--------------------------------------------|
| | - Genotoxicity testing | | |
| | - Micronucleus Test for<br>Genetic Toxicology | | |
| | - Intracutaneous<br>reactivity testing | | |
| | - Maximization and<br>sensitization testing | | |
| | - Pyrogen testing | | |
| | - Acute systemic<br>injection testing | | |
| | - Cytotoxicity testing | | |
| | - Implantation testing | | |
| | - Preclinical safety and<br>efficacy testing | | |
| | - Clinical case series | | |
| Performance | Periodontal<br>Regeneration | Periodontal<br>Regeneration | Periodontal<br>Regeneration |
| Compatibility<br>w/other devices | Can be used with Bone<br>grafting material | Can be used with Bone<br>grafting material | Can be used with Bone<br>grafting material |
| Sterilization<br>Process | Sterile by Gamma<br>Irradiation | Sterile by Gamma<br>Irradiation | Sterile by Gamma<br>Irradiation |
| Chemical safety | Biocompatible | Biocompatible | Biocompatible |
| Anatomical sites | Oral, Periodontal | Oral, Periodontal | Oral, Periodontal |
| Non-Pyrogenic | Yes | Yes | Yes |
| Shelf-Life | 36 Months | 36 Months | 36 Months |

# Brief Summary of Data Submitted

The Sponsor evaluated the performance characteristics of GuidOss® and Bio-Gide® with a thorough chemical and physical characterization. The physical and chemical characteristics of the products were found to be comparable. Further, in several animal studies, both products were found to grow new bone and be subsequently resorbed at similar rates. Finally, in a clinical case series, use of GuidOss® resulted in defect healing and formation of new bone of sufficient quality to obtain dental implant placement.

{6}------------------------------------------------

GuidOss was the subject of the full range of biocompatibility tests recommended in the FDA's "Class II Special Controls Guidance Document: Dental Bone Grafting Devices" and in accordance with ISO 10993. Test results confirmed product safety. GuidOss® is made from pure type I collagen membrane obtained by a standardized controlled manufacturing process. The type I collagen has been purified from veterinary certified porcine skin. Further, the product is sterilized to achieve a sterility assurance level SAL 1 x 10°6.

Based on the information presented herein, it has been demonstrated that GuidOss® is substantially equivalent to Bio-Gide®, and safe and effective for the proposed indications for use.

#### Conclusion

The GuidOss® presents the same types of potential risks to consumers as the predicate device Bio-Gide®, and has controlled these risks in a similar manner. Accordingly, GuidOss® is expected to be safe and effective for its intended uses. And biocompatibility tests and compatibility test show that the device meets the requirements of those standards.

Literatures and post market experience show that the device is substantially equivalent. Comparison with the predicate device shows that the device has similar specification and performance. Therefore, it is concluded that GuidOss® are substantially equivalent to the predicate device.